(21 days)
Not Found
No
The summary describes a mechanical knee implant system and does not mention any software, algorithms, or AI/ML capabilities.
Yes
The device is a total knee replacement system, which means it is meant to treat medical conditions by replacing damaged knee joints.
No.
The device is a total knee replacement system, which is a therapeutic device intended for surgical implantation, not for diagnosis.
No
The device description clearly details physical components made of Cobalt Chromium alloy, UHMWPE, and Titanium alloy, which are hardware materials, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for "total knee replacement" in skeletally mature individuals due to various conditions affecting the knee joint. This is a surgical implant, not a diagnostic test performed on biological samples.
- Device Description: The description details the materials and design of the physical components of a knee replacement system (femoral components, tibial inserts, tibial trays, tibial augments). These are all physical parts intended to be implanted in the body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
Therefore, this device falls under the category of a surgical implant, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The OPTETRAK® Total Knee Systems are indicated for use in skeletally mature individuals undergoing primary surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. They are also indicated for revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present.
CAUTION: For cemented use only in the USA.
Product codes (comma separated list FDA assigned to the subject device)
JWH
Device Description
Femoral Components
The proposed Optetrak Line Extension (Size 0) femoral components are composed of Cobalt Chromium alloy (ASTM F-75). The proposed Size 0 femoral component is available in the cruciate retaining (CR) and posterior stabilized (PS) styles. The design incorporates the same design features as the predicate Optetrak femoral components on a smaller scale. The existing Optetrak patellar components (#K932690) are fully compatible with the proposed Optetrak Line Extension (Size 0) femoral components.
Tibial Components
The proposed Line Extension (Size 0 and 1 Delta) tibial inserts are composed of Ultra High Molecular Weight Polyethylene - UHMWPE (ASTM F648). The proposed insert components for the Size 0 are available in the cruciate retaining (CR) and posterior stabilized (PS) styles, similar to those in the existing Optetrak system. The proposed insert components for the Size 1 Delta are available in cruciate retaining (CR), posterior stabilized (PS), and constrained condylar (CC) styles, similar to those in the existing Optetrak system. The predicate and proposed models have the same locking mechanism . for assembly of the polymer insert into the tibial trav.
In addition, the CC spine stiffener screw line has been expanded to accommodate the Size 1 Delta CC tibial inserts. This screw acts as a stabilizing force in the spine of the CC tibial insert. The screw varies in length according to tibial insert thickness and is packaged with the appropriate insert.
Tibial Tray Components
Optetrak Line Extension (Size 0 and 1 Delta) tibial tray components are designed to accept the modular tibial insert (described above). The proposed tibial tray components are composed of Titanium alloy (Ti 6Al 4V), which is the same as the predicate Optetrak trays. The locking mechanism is identical to that of the predicate Optetrak system. Similarly, the proposed line extension offers a finned stem tray version and a trapezoid stem tray version. Both designs have tibial component options that allow for upsizing and downsizing on the tibia.
Augmentation Components
The proposed Optetrak Line Extension (Size 0 and 1 Delta) tibial augment components are designed to work with their corresponding Size 0 and 1 Delta trapezoid tibial trays. The components are composed of Titanium alloy (Ti 6 Al 4V) conforming to ASTM F136.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
knee
Indicated Patient Age Range
skeletally mature individuals
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Design assurance reviews were conducted to verify that the implant performance would be adequate for anticipated in vivo loading. These activities did not indicate the need for additional testing beyond that performed for validation of the previously mentioned predicate Optetrak models.
We conclude that the Optetrak Size 0 / 1 Delta components are substantially equivalent to other devices legally marketed in the United States, most notably Exactech's predicate Optetrak products.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
#K932690, #K933494, #K935726, #K933610, #K932776, #K954208, #K932776, #K936079, #K933610, #K933610
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis.
(a)
Identification. A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.
0
2320 NW 66TH COUR GAINESVILLE, FL 3265
352-377-1140 FAX 352-378-2617
JUL 1 6 2001
Exactech® Optetrak ™ Total Knee System Size 0 / 1 Delta Line Extension
510(k) Summary of Safety and Effectiveness Special 510(k)
Sponsor:
Exactech® Inc. 2320 N.W. 66th Court Gainesville, Florida 32653
| Phone: | (352) - 377 - 1140 |
|---|---|
| Fax: | (352) - 378 - 2617 |
FDA Establishment Number 1038671
Contact: Gary J. Miller, Ph.D. V.P. of Research and Development
Date:
June 13, 2001
Section 4 Page 1 of 5
1
510(k) Summary of Safety and Effectiveness Special 510(k)
Classifications / Proprietary Names:
Classification Name:
Prosthesis, knee, patellofemorotibial, semi-contrained, cemented, polymer/metal polymer
Trade / Proprietary Model Names:
Optetrak Total Knee System Size 0 / 1 Delta
JWH Product Code: C.F.R. Section: 888.3560
Device Class: II
Classification Panel: Orthopedic
Legally Marketed Devices for Substantial Equivalence Comparison:
| Exactech Predicate Devices | ||
|---|---|---|
| Model | Manufacturer | 510(k) Number |
| Optetrak CR Femoral | Exactech | #K932690 |
| Optetrak PS Femoral | Exactech | #K933494 |
| Optetrak Porous CR Femoral | Exactech | #K935726 |
| Optetrak PS Tibial Insert | Exactech | #K933610 |
| Optetrak CR Tibial Insert | Exactech | #K932776 |
| Optetrak CC Tibial Insert | Exactech | #K954208 |
| Optetrak Finned Tibial Tray | Exactech | #K932776 |
| Optetrak Finned Porous Tibial Tray | Exactech | #K936079 |
| Optetrak Trapezoidal Tibial Tray | Exactech | #K933610 |
| Optetrak Tibial Augments | Exactech | #K933610 |
Predicate Devices from other Manufacturers
| Nexgen | Zimmer | ---------- |
|---|---|---|
| Maxim | Biomet | ---------- |
| PFC | Johnson & Johnson | ---------- |
2
510(k) Summary of Safety and Effectiveness Special 510(k)
Device Information:
INDICATIONS
The OPTETRAK® Total Knee Systems are indicated for use in skeletally mature individuals undergoing primary surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. They are also indicated for revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present.
CAUTION: For cemented use only in the USA.
CONTRAINDICATIONS
The OPTETRAK® Total Knee Systems are contraindicated in patients with active infection, patients without sufficient bone stock to allow appropriate insertion and fixation of the prosthesis, patients without sufficient soft tissue integrity to provide adequate stability, and in patients with either mental or neuromuscular disorders that do not allow control of the knee joint, and in patients whose weight, age, or activity level might cause extreme loads and early failure of the system.
DEVICE DESCRIPTION
Femoral Components
The proposed Optetrak Line Extension (Size 0) femoral components are composed of Cobalt Chromium alloy (ASTM F-75). The proposed Size 0 femoral component is available in the cruciate retaining (CR) and posterior stabilized (PS) styles. The design incorporates the same design features as the predicate Optetrak femoral components on a smaller scale. The existing Optetrak patellar components (#K932690) are fully compatible with the proposed Optetrak Line Extension (Size 0) femoral components.
Tibial Components
The proposed Line Extension (Size 0 and 1 Delta) tibial inserts are composed of Ultra High Molecular Weight Polyethylene - UHMWPE (ASTM F648). The proposed insert components for the Size 0 are available in the cruciate retaining (CR) and posterior stabilized (PS) styles, similar to those in the existing Optetrak system. The proposed insert components for the Size 1 Delta are available in cruciate retaining (CR), posterior stabilized (PS), and constrained condylar (CC) styles, similar to those in the existing Optetrak system. The predicate and proposed models have the same locking mechanism . for assembly of the polymer insert into the tibial trav.
Section 4 Page 3 of 5
3
510(k) Summary of Safety and Effectiveness Special 510(k)
In addition, the CC spine stiffener screw line has been expanded to accommodate the Size 1 Delta CC tibial inserts. This screw acts as a stabilizing force in the spine of the CC tibial insert. The screw varies in length according to tibial insert thickness and is packaged with the appropriate insert.
Tibial Tray Components
Optetrak Line Extension (Size 0 and 1 Delta) tibial tray components are designed to accept the modular tibial insert (described above). The proposed tibial tray components are composed of Titanium alloy (Ti 6A1 4 V), which is the same as the predicate Optetrak trays. The locking mechanism is identical to that of the predicate Optetrak system. Similarly, the proposed line extension offers a finned stem tray version and a trapezoid stem tray version. Both designs have tibial component options that allow for upsizing and downsizing on the tibia.
Augmentation Components
The proposed Optetrak Line Extension (Size 0 and 1 Delta) tibial augment components are designed to work with their corresponding Size 0 and 1 Delta trapezoid tibial trays. The components are composed of Titanium alloy (Ti 6 Al 4V) conforming to ASTM F136.
| Material | Composition |
|---|---|
| Inner / Outer Trays | PETG - 0.040" thickness |
| Tray Lids | Spun-Bonded Olefin - Tyvek® |
| Inserts | Medium grade LD45 Foam |
| Box | Heavy weight cardboard |
| Outer Shrink-Wrap | Clear, Light-Weight Plastic |
| Shipping Cartons | Heavy-weight Corrugated Cardboard |
PACKAGING MATERIALS
STERILIZATION INFORMATION
Method: Gamma radiation (Cobalt 60 source) Dose: 25 - 37 kGy Sterility Assurance Level (SAL): 10-6
4
510(k) Summary of Safety and Effectiveness Special 510(k)
PERFORMANCE DATA
Design assurance reviews were conducted to verify that the implant performance would be adequate for anticipated in vivo loading. These activities did not indicate the need for additional testing beyond that performed for validation of the previously mentioned predicate Optetrak models.
We conclude that the Optetrak Size 0 / 1 Delta components are substantially equivalent to other devices legally marketed in the United States, most notably Exactech's predicate Optetrak products.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle is enclosed in a circle, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" surrounding the upper portion of the circle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 1 6 2001
Gary J. Miller, Ph.D. Vice President of Research and Development Regulatory Representative Exactech, Inc 2320 N.W. 66th Court Gainesville, Florida 32653
Re: K011976
Trade Name: Optetrak Total Knee System Size 0/1 Delta Regulation Number: 888.3560 Regulatory Class: II Product Code: JWH Dated: June 21, 2001 Received: June 25, 2001
Dear Dr. Miller:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through perrodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
6
Page 2 - Gary J. Miller, Ph.D.
This letter will allow you to begin marketing your device as described in your - 10kk) premarket I his letter will anow you to begin marketing your arence of your device to a legally marketed notification. The IDA intimation of substantial equal device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFF Part 801 and If you desire specific advice for your actives on our can research the Office of Compliance at additionally 809.10 for mi vitio diagnostions on the promotion and advertising of your device, (301) 594-4039. Additionally, for quest 213-01) 594-4639. Also, please note the regulation please contact the Office of Compilance at (301) of CFR 807.97). Other general entitled, "Misoranding by relected to premation news be obtained from the Division of Small
information on your responsibilities under the Act may 1901) 142, 6507 and information on your responsibilities and in 1991 million (800) 638-2041 or at its Manufacturers "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Mark N-Mullinson
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Exactech® Optetrak Total Knee System Size 0 / 1 Delta
Indications for Use
510(k) Number:
Device Name:
Optetrak Total Knee System Size 0 / 1 Delta
INDICATIONS
The OPTETRAK® Total Knee Systems are indicated for use in skeletally mature individuals undergoing primary surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. They are also indicated for revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present.
CAUTION: For cemented use only in the USA.
CONTRAINDICATIONS
The OPTETRAK® Total Knee Systems are contraindicated in patients with active infection, patients without sufficient bone stock to allow appropriate insertion and fixation of the prosthesis, patients without sufficient soft tissue integrity to provide adequate stability, and in patients with either mental or neuromuscular disorders that do not allow control of the knee joint, and in patients whose weight, age, or activity level might cause extreme loads and early failure of the system.
Mark n Milkeran
(Division Sign-Off) Division of General, Restorative and Neurological Devices
510(k) Number.
Please do not write below this line - use another page if needed
Concurrence of CDRH, Office of Device Evaluation7(ODE)
Prescription Use
$\eta^{er}$
or
Over the Counter Use
No